Prescription medicine
Trandolapril First approved as Mavik
Trandolapril (Mavik) is a prescription medicine with an FDA approval on record since 1996. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $0.157 per trandolapril 1 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the trandolapril FDA label on DailyMed (effective October 31, 2025, Lupin Pharmaceuticals, Inc.); the NDA 20528 record on Drugs@FDA; every trandolapril label on DailyMed.
Highlights of the record
FDA label of October 31, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
FETAL TOXICITY.
When pregnancy is detected, discontinue trandolapril tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (See WARNINGS : Fetal Toxicity ).
Used for
From the label: indications and usageHypertension Trandolapril tablets are indicated for the treatment of hypertension.
Forms and strengths
- 1 mg
- 2 mg
- 4 mg
Tablet.
On the market
- Earliest approval on file
- April 26, 1996 Mavik, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 10 first December 12, 2006; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 5 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.157 per tablet Trandolapril 1 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 2,026 through July 30, 2026
What is trandolapril used for?
From the label: indications and usageHypertension Trandolapril tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. […]
Conditions named in the indications of trandolapril's FDA labels, with every medicine labeled for each:
From other trandolapril labelsHigh blood pressure: INDICATIONS AND USAGE Hypertension Trandolapril tablets are indicated for the treatment of hypertension.
FDA pharmacologic class: Angiotensin Converting Enzyme Inhibitor.
Source: FDA drug label (Trandolapril), Lupin Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8143a6cf-dadc-4ef7-a8db-d16d7150ad34), via openFDA; the full label on DailyMed
Is there a generic for trandolapril (Mavik)?
The FDA approved the first generic trandolapril on December 12, 2006. 10 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists trandolapril from 5 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1996 earliest approval on file
- 2006 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for trandolapril (Mavik)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.157 per Trandolapril 1 mg tablet, up 1% from $0.155 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Trandolapril 4 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Trandolapril 1 mg tablet | Generic | $0.157 per tablet | $4.71 | +1% |
| Trandolapril 2 mg tablet | Generic | $0.162 per tablet | $4.87 | -11% |
| Trandolapril 4 mg tablet | Generic | $0.156 per tablet | $4.68 | -23% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the trandolapril label say about other medicines?
The trandolapril label names 15 other medicines in its interaction, contraindication or warning sections. The labels of 1 other medicine name trandolapril. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aliskiren | contraindications | Do not co-administer aliskiren with trandolapril tablets in patients with diabetes (see PRECAUTIONS , Drug Interactions). |
| Amiloride | drug interactions | Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. |
| Captopril | warnings | Neutropenia/Agranulocytosis Another ACE inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression rarely in patients with uncomplicated hypertension, but more frequently in patients with renal impairment, especially if they also have a collagen-vascular disease such as systemic lupus … |
| Cimetidine | drug interactions | Coadministration of trandolapril and cimetidine led to an increase of about 44% in C max for trandolapril, but no difference in the pharmacokinetics of trandolaprilat or in ACE inhibition. |
| Digoxin | drug interactions | Drug Interactions Trandolapril did not affect the plasma concentration (pre-dose and 2 hours post-dose) of oral digoxin (0.25 mg). |
| Epinephrine | warnings | Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, emergency therapy, including but not limited to subcutaneous epinephrine solution 1:1,000 (0.3 to 0.5 mL) should be promptly administered. … |
| Everolimus | drug interactions | Mammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS – Head and Neck Angioedema ). |
| Furosemide | drug interactions | Coadministration of trandolapril and furosemide led to an increase of about 25% in the renal clearance of trandolaprilat, but no effect was seen on the pharmacokinetics of furosemide or trandolaprilat or on ACE inhibition. |
| Lithium | drug interactions | Lithium Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. |
| Sacubitril and valsartan | contraindications | Do not administer trandolapril tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS ). |
| Sirolimus | drug interactions | Mammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS – Head and Neck Angioedema ). |
| Spironolactone | drug interactions | Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. |
| Temsirolimus | drug interactions | Mammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS – Head and Neck Angioedema ). |
| Triamterene | drug interactions | Use of potassium-sparing diuretics (spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes concomitantly with ACE inhibitors can increase the risk of hyperkalemia. |
Every other medicine the trandolapril label names
| Medicine named | Section | What the label says |
|---|---|---|
| Warfarin | drug interactions | The anticoagulant effect of warfarin was not significantly changed by trandolapril. |
Source: FDA drug label (Trandolapril), Lupin Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8143a6cf-dadc-4ef7-a8db-d16d7150ad34), via openFDA; the full label on DailyMed
What do FAERS reports show for trandolapril?
The FDA Adverse Event Reporting System holds 2,026 reports that list trandolapril among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 195 are coded as a death and 1,008 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as trandolapril?
71 other medicines are given the same way (oral) and in the same FDA class as trandolapril or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Enalapril | High blood pressure | 29 labelers | $0.0664 per tablet 10 mg tablet | No current entry |
| Hydrochlorothiazide and lisinopril | High blood pressure | 27 labelers | $0.0293 per tablet 10-12.5 mg tablet | No current entry |
| Amlodipine and benazepril | High blood pressure | 16 labelers | $0.114 per unit 10-20 mg | No current entry |
| Benazepril | High blood pressure | 21 labelers | $0.0789 per tablet 20 mg tablet | No current entry |
| Ramipril | High blood pressure | 17 labelers | $0.0707 per capsule 10 mg capsule | No current entry |
| Captopril | High blood pressure | 13 labelers | $0.228 per tablet 12.5 mg tablet | No current entry |
| Quinapril | High blood pressure | 9 labelers | n/a | In shortage |
Every medicine labeled for the same conditions as trandolapril
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does trandolapril compare with medicines for the same use?
2 side-by-side pages set trandolapril beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to trandolapril
- 71 medicines for the same use
- Other ACE inhibitors
- the pharmacologic class, with prices and generics
- Trandolapril side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other